NCT00875693View on ClinicalTrials.gov

A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory and Relapsed Acute Myelogenous Leukemia (AML)

PHASE1CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

June 2, 2009

Primary Completion Date

June 30, 2014

Study Completion Date

December 27, 2017

Conditions
Acute Myelogenous LeukemiaMyelodysplastic Syndrome
Interventions
DRUG

CPX-351

CPX-351 is a liposomal formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin. The two drugs are present inside the liposome in a 5:1 molar ratio.

Trial Locations (1)

10021

Weill Cornell Medical College, New York

Sponsors

Collaborators (1)

Jazz Pharmaceuticals
All Listed Sponsors
collaborator

Jazz Pharmaceuticals

INDUSTRY

lead

Weill Medical College of Cornell University

OTHER